Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Octopus to spin off tech arm Kraken

(Sharecast News) - Octopus Energy is to spin off Kraken, its fast-growing technology unit, the British gas and electricity provider confirmed on Thursday. Developed initially for use within Octopus, Kraken's AI-powered platform has since been licensed to numerous other utilities.

It is contracted to serve more than 70m household and business accounts worldwide, with $500m in committed annual revenues from clients including EDF, E.ON Next and National Grid US.

Octopus said spinning out the business would accelerate Kraken's global expansion, allowing it to fast-track technology investments and expand into new energy markets.

Greg Jackson, chief executive of Octopus, said Kraken was a now a "huge and successful" business in its own right.

He continued: "I set the embarrassingly low goal of 100m accounts by 2027; it looks like it'll beat that and can now aim to serve 1bn people over the next decade."

Tim Wan, formerly of software firm Asana, has been appointed Kraken's chief financial officer to oversee the spin-off with chief executive Amir Orad.

No specifics have yet been provided, although Octopus's owners are expected to retain a holding.

According the Financial Times, citing unnamed people familiar with the matter, the business could eventually be listed in either New York or London, with a value of around $10bn.

Wan oversaw Asana's market listing when he was chief financial officer at the US company.

Octopus is owned by a number of pension funds and other investors, including Japanese utility Tokyo Gas, Australia's Origin Energy and US fund Generation Investment Management.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.